Johnson & Johnson Website

Johnson & Johnson

NYSE-JNJ

Company Overview

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

  • Name

    Johnson & Johnson

  • CEO

    —

  • Website

    www.jnj.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1886

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • J&J's strong position in oncology (Darzalex and Carvykti) and next-generation immunology product Tremfya (following Stelara) create a foundation of innovative drugs.

  • Diverse healthcare segments help insulate J&J from downturns in the overall economy, offering a defensive growth opportunity with a steady and likely growing dividend.

  • Several of J&J's key next-generation pipeline drugs are specialty drugs that tend to carry strong pricing power as well as lower regulatory hurdles for approval.

Bears Say

  • J&J's late-stage drug pipeline could face significant competitive threats, as oncology and immunology remain popular areas for biopharma investment.

  • Biosimilar competition to Stelara is rapidly eroding sales of the drug, putting pressure on the rest of the portfolio to compensate.

  • J&J's orthopedics segment is struggling to maintain share against more focused players like Stryker and Zimmer Biomet.

Source: Morningstar Analysis - Oct 14, 2025

What's happening

Nov 15, 2025 - Dec 17, 2025

Johnson & Johnson Achieves Significant Growth Amid Positive Developments

  • Johnson & Johnson's stock reached an all-time high of $212.29, driven by advancements in its oncology portfolio.
  • The company secured FDA approvals for key treatments, enhancing investor confidence and market position.
  • Strategic acquisition of Halda Therapeutics signals JNJ's commitment to expanding into higher-growth therapeutic areas.

Over the past month, Johnson & Johnson (JNJ) has demonstrated a robust performance with an overall increase of 9.3%. This rise significantly outpaced the S&P 500's return of 1.3%, highlighting JNJ's strong market position during this period. The company's stock peaked at $212.29 on December 15 due to positive developments in its oncology portfolio and favorable analyst ratings that underscored its growth potential.

Key events contributing to JNJ’s upward trajectory included significant FDA approvals for treatments such as Tecvayli for multiple myeloma and Akeega for BRCA2-mutated prostate cancer. These approvals validated the efficacy of JNJ’s products and bolstered investor confidence regarding future revenue streams. Additionally, Bank of America raised its price target from $204 to $220 based on these promising advancements, further fueling bullish sentiment around the stock.

The recent acquisition of Halda Therapeutics for $3.05 billion also played a crucial role in enhancing JNJ's oncology pipeline while signaling strategic growth ambitions within solid tumor therapies—an area expected to yield higher returns in the future. Despite some bearish sentiments stemming from challenges with certain clinical trials, including discontinuation of a Phase 3 study involving milvexian, the overall market reaction remained positive due to ongoing successes across other therapeutic areas.

Social media discussions reflected optimism about sales projections reaching between $93 billion and $125 billion by 2030 while highlighting strong financial metrics like a net margin exceeding 27%. Analysts maintained high ratings across various firms, reinforcing confidence among investors regarding JNJ’s operational resilience amidst broader market fluctuations.

Johnson & Johnson outperformed both the Health Care sector (XLV), which saw gains below those achieved by JNJ at just over 1%, and exceeded expectations relative to general market indices like the S&P 500 during this timeframe; thus demonstrating effective management strategies amid evolving healthcare demands.

NYSE:JNJ